The Behavioral and Field Research Core (BFRC) is designed to facilitate the integration of communication and behavioral research across the Cancer Center by translating research findings from the behavioral sciences into work in epidemiology, cancer prevention, clinical and developmental therapeutics, palliative care, and genetics. Resources available through BFRC include real-time video recording and coding of clinical interactions, access to an extensive video archive for communication and behavioral studies geographical and population tracking/mapping capabilities, community research participant registries at KCI access to comprehensive national datasets (e.g., HINTS, Health and Retirement Survey), as well as an extensive bank of clinical and social/behavioral instruments and measures. The Core offers expertise in communication science and behavioral research methodologies, design and evaluation of evidence-based social and behavioral interventions (including social marketing as a systematic approach to population level behavior change), social network methodology and analysis, quality of life measurement utilizing the most appropriate instruments, ecological momentary assessment, and electronic daily diaries (QOL has emerged as a critical factor in developmental therapeutic trials), and community based participatory research, particularty related to health disparities. The Core maintains an active network of community organization partnerships across the Institute's catchment area. Community partners participate in Research Advisory Committees and Community Advisory Committees, providing community perspective, input and facilitating access to the populations they serve. Through these partnerships the Core facilitates community access for Institute researchers, thus serving to assist in the translation and dissemination of behavioral research.
Expertise, technological skills and equipment within the BFRC allow investigators interested in behavioral and communication research to move quickly into data capture, codebook development, coding and analysis, particulariy of real time observational data. Investigators can readily conduct community based participatory research because the BFRC has built a trusted presence through the network of community partners. Currently, the BFRC is the only facility of its kind available to cancer center members and the WSU community.
|Neslund-Dudas, Christine M; McBride, Russell B; Kandegedara, Ashoka et al. (2018) Association between cadmium and androgen receptor protein expression differs in prostate tumors of African American and European American men. J Trace Elem Med Biol 48:233-238|
|Kraniak, Janice M; Chalasani, Anita; Wallace, Margaret R et al. (2018) Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening. Exp Neurol 299:289-298|
|An, Myunggi; Yu, Chunsong; Xi, Jingchao et al. (2018) Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity. Nanoscale 10:9311-9319|
|Tamura, Koji; Yu, Jun; Hata, Tatsuo et al. (2018) Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proc Natl Acad Sci U S A 115:4767-4772|
|Wu, Jheng-Yu; Xiang, Shengyan; Zhang, Mu et al. (2018) Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity. J Biol Chem 293:1976-1993|
|Negmeldin, Ahmed T; Knoff, Joseph R; Pflum, Mary Kay H (2018) The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Eur J Med Chem 143:1790-1806|
|Bao, Xun; Wu, Jianmei; Sanai, Nader et al. (2018) A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor. J Pharm Anal 8:20-26|
|Matherly, Larry H; Hou, Zhanjun; Gangjee, Aleem (2018) The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer. Cancer Chemother Pharmacol 81:1-15|
|Pollack, Murray M; Holubkov, Richard; Reeder, Ron et al. (2018) PICU Length of Stay: Factors Associated With Bed Utilization and Development of a Benchmarking Model. Pediatr Crit Care Med 19:196-203|
|Ali, Arif N; Zhang, Peixin; Yung, W K Alfred et al. (2018) NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol 137:39-47|
Showing the most recent 10 out of 826 publications